Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
MYPI2025006873A0Undetermined Publication Date: 2020-11-13REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2025006873
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-05-12
- Filing Date
- 2020-05-12
- Publication Date
- 2020-11-13
Abstract
The present disclosure provides methods for treating or inhibiting the growth of cancer comprising selecting a patient with cancer and administering a therapeutically effective amount of a LAG-3 inhibitor in combination with a therapeutically effective amount of a PD-1 inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In certain embodiments, the administration of the PD-1 inhibitor enhances the efficacy of a LAG-3 inhibitor (e.g., an anti-LAG-3 antibody or antigen-binding fragment thereof) in inhibiting the growth of cancer.
Need to check novelty before this filing date? Find Prior Art
